JohnM.McCartyMD

Oncology • Richmond, VA

VCU Massey Cancer Center Bone Marrow Transplantation Program

Join to view full profile

Dr. McCarty is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. McCarty's full profile

Already have an account?

Office
1300 E Marshall St
Mailstop 981057
Richmond, VA 23298
Phone+1 804-828-4596

Fax+1 804-628-0827
Is this information wrong?

Summary

Dr. John McCarty is the Medical Director of the Cellular Immunotherapy and Transplantation Program at VCUHS Massey Cancer Center in Richmond VA. He is also the head of the Cellular Immunotherapy Laboratory there. . He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 31 years. He also speaks multiple languages, including Spanish. He specializes in Cellular Immunotherapy such as CARt cells and in all forms of autologous and allogeneic stem cell transplantation. He is currently the G Watson James Endowed Professor of Hematology.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1989 - 1993
Tufts Medical CenterResidency, Internal Medicine, 1986 - 1989
Icahn School of Medicine at Mount SinaiClass of 1986
Princeton UniversityAB, Biochemistry, Cum Laude, 1978 - 1982

Certifications & Licensure

VA State Medical License 1996 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

G Watson James Endowed Professor of Hematology Virginia Commonwealth University, 2018
Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation Start of enrollment: 1997 Apr 01
Terminated
Phase 3
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome Start of enrollment: 2008 Jul 01
Completed
Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Start of enrollment: 2014 Jul 01
Terminated
Phase 2
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) Start of enrollment: 2015 Aug 01
Completed
Phase 3
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) Start of enrollment: 2015 Aug 01
Completed
Phase 2
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Start of enrollment: 2016 Dec 20
Completed
Phase 1, Phase 2
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2016 Dec 01
Completed
Phase 2
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501) Start of enrollment: 2016 Oct 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Simultaneous exercise stress cardiac magnetic resonance and cardiopulmonary exercise testing to elucidate the Fick components of aerobic exercise capacity: a feasibili...
Justin M Canada, John McCarty, Jennifer H Jordan, Cory R Trankle, Kevin DeCamp, Josh D West, Mary Ann Reynolds, Rachel Myers, Katey Sweat, Virginia McGhee, Ross Arena,...> ;Cardio-Oncology. 2023 Jul 10
4 citations
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation
Peter A. Riedell, Mehdi Hamadani, Kwang Woo Ahn, Carlos Litovich, Claudio G. Brunstein, Amanda F. Cashen, Jonathon B. Cohen, Narendranath Epperla, Brian T. Hill, Annie...> ;British Journal of Haematology. 2021 Sep 28
61 citations
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide
Bronwen E. Shaw, Antonio Jimenez-Jimenez, Linda J. Burns, Brent R. Logan, Farhad Khimani, Brian C. Shaffer, Nirav N. Shah, Alisha Mussetter, Xiao Ying Tang, John M. Mc...> ;Journal of Clinical Oncology. 2021 Apr 27
6 citations
Killer Immunoglobulin-Like Receptor-Ligand Interactions Predict Clinical Outcomes following Unrelated Donor Transplantations
Elizabeth Krieger, Roy T. Sabo, Sanauz Moezzi, Caitlin N. Cain, Catherine H. Roberts, Pamela Kimball, Alden Chesney, John M. McCarty, Armand Keating, Rizwan Romee, Chr...> ;Biology of Blood and Marrow Transplantation. 2020 Apr 1
5 citations
Bronchoalveolar lavage to evaluate new pulmonary infiltrates in allogeneic hematopoietic stem cell transplant recipients: impact on antimicrobial optimization
Nicole C. Vissichelli, Kristin Miller, John M. McCarty, Catherine H. Roberts, Michael P. Stevens, O. De La Cruz> ;Infection Prevention in Practice. 2019 Dec 1
17 citations
Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
John Preston Claiborne, Dipankar Bandyopathyay, Catherine H. Roberts, Kelly G. Hawks, May Aziz, Gary Lee Simmons, Christina M. Wiedl, Harold M. Chung, William B. Clark...> ;Leukemia & Lymphoma. 2019 May 3
10 citations
Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study
Michael A. Pulsipher, Brent R. Logan, Pintip Chitphakdithai, Deidre M. Kiefer, Marcie L. Riches, J. Douglas Rizzo, Paolo Anderlini, Susan F. Leitman, James W. Varni, H...> ;Biology of Blood and Marrow Transplantation. 2019 Apr 1
12 citations
Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors
Michael A. Pulsipher, Brent R. Logan, Deidre M. Kiefer, Pintip Chitphakdithai, Marcie L. Riches, J. Douglas Rizzo, Paolo Anderlini, O'Susan F Leitman, Hati Kobusingye,...> ;Haematologica. 2019 Apr 1
1 citations
Autologous stem-cell transplant for metastatic renal medullary carcinoma
Marcus A. Carden, Eva Perdahl-Wallace, Jay Greenberg, John M. McCarty> ;Pediatric Blood & Cancer. 2018 Sep 1
27 citations
Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
Kathryn T. Maples, Roy T. Sabo, John M. McCarty, Amir A. Toor, Kelly G. Hawks> ;Leukemia & Lymphoma. 2018 Apr 4
3 citations
The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.
David J. Kobulnicky, Roy T. Sabo, Shashank Sharma, Ali S. Shubar Ali, Kristen M. Kobulnicky, Catherine H. Roberts, William B. Clark, Harold M. Chung, John M. McCarty, ...> ;Leukemia & Lymphoma. 2018 Apr 4
70 citations
The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future
Tessa M. Andermann, Jonathan U. Peled, Christine M. Ho, Pavan Reddy, Marcie L. Riches, Rainer Storb, Takanori Teshima, Marcel R.M. van den Brink, Amin M. Alousi, Sophi...> ;Biology of Blood and Marrow Transplantation. 2018 Feb 19
33 citations
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report
Ivana N. Micallef, Patrick J. Stiff, Auayporn Nademanee, Richard T. Maziarz, Mitchell E. Horwitz, Edward A. Stadtmauer, Jonathan L. Kaufman, John M. McCarty, Rita Varg...> ;Biology of Blood and Marrow Transplantation. 2018 Jun 1
13 citations
Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis
Noah S. Kalman, Nitai D. Mukhopadhyay, Catherine H. Roberts, Harold M. Chung, William B. Clark, John M. McCarty, Amir A. Toor, S. Song> ;Leukemia & Lymphoma. 2017 May 31
9 citations
Treatment of acute fibrinous organizing pneumonia following hematopoietic cell transplantation with etanercept
Gary Lee Simmons, Harold M. Chung, John M. McCarty, Amir A. Toor, D Farkas, Kristin Miller, William B. Clark> ;Bone Marrow Transplantation. 2017 Jan 1
2 citations
Effectiveness and toxicity of high-dose cyclophosphamide in obese versus non-obese patients receiving allogeneic hematopoietic stem cell transplant.
Melissa R. Hunter, Roy T. Sabo, John M. McCarty, Ashley M Newland> ;Journal of Oncology Pharmacy Practice. 2016 Feb 1
52 citations
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: A phase 1-2 dose de-escalation study
Paolo Anderlini, Juan Wu, Iris D. Gersten, Marian Ewell, Jakob Tolar, Joseph H. Antin, Roberta H. Adams, Sally Arai, Gretchen Eames, Mitchell E. Horwitz, John M. McCar...> ;The Lancet. Haematology. 2015 Sep 1
18 citations
Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.
Lauren M. Curtis, Manuel B. Datiles, Seth M. Steinberg, Sandra A. Mitchell, Rachel Bishop, Edward W. Cowen, Jacqueline W. Mays, John M. McCarty, Zoya Kuzmina, Filip Pi...> ;Haematologica. 2015 Jun 18
19 citations
Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.
Amir A. Toor, Roy T. Sabo, Catherine H. Roberts, Bonny L. Moore, S. R. Salman, Allison F. Scalora, May T. Aziz, Ali S. Shubar Ali, Charles E. Hall, Jeremy Meier, Radhi...> ;Biology of Blood and Marrow Transplantation. 2015 Jul 1
10 citations
Stem Cell Transplantation as a Dynamical System: Are Clinical Outcomes Deterministic?
Amir A. Toor, Jared Kobulnicky, Salman Salman, Catherine H. Roberts, Max Jameson-Lee, Jeremy Meier, Allison F. Scalora, Nihar U. Sheth, Vishal N. Koparde, Myrna G. Ser...> ;Frontiers in Immunology. 2014 Dec 3
69 citations
Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201
Edmund K. Waller, Brent R. Logan, Wayne Harris, Steven M. Devine, David L. Porter, Shin Mineishi, John M. McCarty, Corina E. Gonzalez, Thomas R. Spitzer, Oleg I. Krija...> ;Journal of Clinical Oncology. 2014 Aug 1
260 citations
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Sergio Giralt, Luciano J. Costa, Jeffrey Schriber, John F. DiPersio, Richard T. Maziarz, John M. McCarty, Paul J. Shaughnessy, Edward L. Snyder, William I. Bensinger, ...> ;Biology of Blood and Marrow Transplantation. 2014 Mar 1
73 citations
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB ...
Meir Wetzler, Dorothy Watson, Wendy Stock, Gregory Koval, Flora Mulkey, Eva Hoke, John M. McCarty, William Blum, Bayard L. Powell, Guido Marcucci, Clara D. Bloomfield,...> ;Haematologica. 2014 Jan 1
22 citations
Pharmacoeconomics of Hematopoietic Stem Cell Mobilization: An Overview of Current Evidence and Gaps in the Literature
Paul J. Shaughnessy, Nelson J. Chao, J. Shapiro, Kent Walters, John M. McCarty, Sunil Abhyankar, Sepideh Shayani, Pieter Helmons, Helen Leather, Amy Pazzalia, Simon Pi...> ;Biology of Blood and Marrow Transplantation. 2013 Sep 1
29 citations
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
Paul J. Shaughnessy, Joseph P. Uberti, Steve Devine, Richard T. Maziarz, Julie M. Vose, Ivana N. Micallef, Eric N. Jacobsen, John M. McCarty, Patrick J. Stiff, Andrew ...> ;Bone Marrow Transplantation. 2013 Jun 1
Join now to see all

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
Treatment of Acute Fibrinous Organizing Pneumonia Following Hematopoietic Cell Transplantation with Etanercept
K Miller, W B Clark, J M McCarty, A A Toor, H M Chung, Nature

Abstracts/Posters

Hematopoietic Cell Transplantation Donor Selection Reimagined: KIR-KIR Ligand Interactions and a Formalized Donor Risk Index Effective at Predicting Survival
John M. McCarty, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

VCU Massey’s Cellular Immunotherapies and Transplant Program ExpandsJanuary 19th, 2023
Booster Shots Are Coming. Here’s What That Means for VirginiaAugust 20th, 2021
Virginia to Provide 3rd Dose of COVID Vaccine to Immunocompromised PeopleAugust 13th, 2021
Join now to see all